Postmenopausal Osteoporosis

Dennis M. Black, Ph.D., and Clifford J. Rosen, M.D.

A 73-year-old asymptomatic white woman with a history of a Colles fracture of the left radius 10 years earlier presents for evaluation. Dual-energy x-ray absorptiometry reveals a bone mineral density (BMD) T score of −2.8 in the lumbar spine and −2.5 in the total hip. How should this case be managed?

THE CLINICAL PROBLEM

OSTEOPOROSIS RESULTS IN 1.5 MILLION FRACTURES PER YEAR IN THE United States, with the vast majority occurring in postmenopausal women. The disease is characterized by skeletal fragility and microarchitectural deterioration. The conceptual definition of osteoporosis links the high risk of postmenopausal fractures to low BMD and qualitative changes in microarchitecture.1 The prevalence of osteoporosis varies depending on whether it is defined by fracture incidence or by low BMD (a T score of −2.5 or less). For example, there are approximately 300,000 hip fractures per year in the United States, but there are close to 40 million women with low BMD.2 It is estimated that a 50-year-old white woman has a 15 to 20% lifetime risk of hip fracture and a 50% risk of any osteoporotic fracture.3,4 Hip fractures can result in poor quality of life, a dependent living situation, and an increased risk of death.4 Spine fractures are also associated with an increased risk of death, are strong predictors of future fractures, and may result in chronic pain, kyphosis, and a loss of self-esteem.

STRATEGIES AND EVIDENCE

OVERVIEW

The overriding goal in managing postmenopausal osteoporosis is the prevention of future fractures. Therefore, identifying women at the highest risk is a clinical priority. Low BMD, particularly at the hip, is a strong risk factor for fracture: for each 1-SD decrement in BMD, the risk of fracture increases by a factor of 2 to 3.5,6 Hence, most guidelines suggest a single BMD assessment at or around 65 years of age. However, a more comprehensive assessment of clinical risk factors is helpful to define absolute risk for an individual and to select patients for treatment. The Fracture Risk Assessment Tool (FRAX), which was developed by the World Health Organization (www.shef.ac.uk/frax/) on the basis of data from several international cohorts, incorporates established risk factors and BMD at the femoral neck to predict individual 10-year risk of hip or major osteoporotic fracture; its use is endorsed by several professional organizations (Table 1).
Patients who have had recent osteoporotic fractures are at particularly high risk for additional fractures. One strategy for identifying such patients is the use of a fracture liaison service targeted to patients with recent fractures that provides a consultative approach with advice and recommendations for the clinician about diagnosis and treatment; such a service has been shown to be cost-effective. Other high-risk patients are those with secondary osteoporosis due to hyperparathyroidism, multiple myeloma, malabsorption, diabetes mellitus (with or without low BMD), or inflammatory bowel disease. In patients with low BMD or a previous fracture or those being considered for anti-osteoporosis therapy, a single evaluation for vitamin D status is recommended, even in those who take vitamin D supplements.

### Key Clinical Points

**Postmenopausal Osteoporosis**
- Fractures and osteoporosis are common, particularly among older women, and hip fractures can be devastating.
- Treatment is generally recommended in postmenopausal women who have a bone mineral density T score of −2.5 or less, a history of spine or hip fracture, or a Fracture Risk Assessment Tool (FRAX) score indicating increased fracture risk.
- Bisphosphonates (generic) and denosumab reduce the risk of hip, nonvertebral, and vertebral fractures; bisphosphonates are commonly used as first-line treatment in women who do not have contraindications. Teriparatide reduces the risk of nonvertebral and vertebral fractures.
- Osteonecrosis of the jaw and atypical femur fractures have been reported with treatment but are rare. The benefit-to-risk ratio for osteoporosis treatment is strongly positive for most women with osteoporosis.
- Because benefits are retained after discontinuation of alendronate or zoledronic acid, drug holidays after 5 years of alendronate therapy or 3 years of zoledronic acid therapy may be considered for patients at lower risk for fracture.

**Management**

**Nonpharmacologic Options**

**Physical Activity and Modifiable Risk Factors**

Resistance and weight-bearing exercise can increase muscle mass and can transiently increase BMD. Although data from randomized trials are lacking to show that weight-bearing physical activity reduces the risk of fractures, longitudinal studies involving high-resolution computed tomography have shown beneficial effects on skeletal microarchitecture in association with some forms of regular physical activity. Fractures result from falls, and the number of falls and the proportion of falls that result in fractures increase with age. Exercise and balance programs (e.g., yoga and tai chi) may result in improved balance and an increase in muscle tone and may secondarily reduce the risk of falls among some elderly persons. Besides exercise, assessment of the home for hazards, withdrawal of psychotropic medications (when possible), and the use of a multidisciplinary program to assess risk factors are prudent strategies for potentially reducing the risk of falls. Other measures should include counseling about cigarette smoking (which is linked to reduced BMD) and about excess alcohol intake (which can increase the risk of falls).

**Calcium and Vitamin D**

The efficacy of calcium and vitamin D treatment for the prevention of osteoporotic fractures is controversial. In a large randomized trial by the Women’s Health Initiative (WHI) investigators involving more than 36,000 postmenopausal women, calcium (1000 mg of elemental calcium supplementation daily) plus vitamin D (400 IU daily) did not have a significant effect on fractures, although there was evidence of benefit in post hoc subgroup analyses among women 60 years of age or older and among those who were adherent to the assigned regimen. Subsequent meta-analyses of several large trials of both calcium and vitamin D supplementation have shown a small reduction in fracture risk, particularly among the institutionalized elderly or those with a low intake of calcium or vitamin D. However, vitamin D supplementation alone has not been shown to reduce the risk of fractures or increase BMD, although smaller trials have suggested that daily supplementation (but not intermittent high-dose supplementation) may...
modestly reduce the risk of falls.16 Trials of supplemental calcium alone have been too small to inform effects on fracture. In the WHI trial, women assigned to calcium with vitamin D had a 17% higher risk of kidney stones than women assigned to placebo, most likely owing to a high intake of calcium at baseline (approximately 1150 mg per day in each group).14 Standard recommendations for most postmenopausal women with osteoporosis support a total calcium intake of 1000 to 1500 mg per day (through diet, supplements, or both) and a total vitamin D intake of 600 to 800 IU per day.

### Pharmacologic Therapies

#### Classes of Drugs

Pharmacologic agents for the treatment of osteoporosis can be classified as either antiresorptive (i.e., targeting osteoclast-mediated bone resorption) or anabolic (i.e., stimulating osteoblasts to form new bone). Drugs of each type have been shown to improve BMD and reduce the risk of fractures. Table 2 provides information about drugs approved by the Food and Drug Administration (FDA) for the treatment of osteoporosis.

**Estrogen and Selective Estrogen-Receptor Modulators**

Estrogen treatment, with or without progesterone, has direct effects on osteocytes, osteoclasts, and osteoblasts, leading to inhibition of bone resorption and maintenance of bone formation. In the WHI trials, estrogen therapy significantly reduced the incidence of new vertebral, nonvertebral, and hip fractures.17,18 Both low-dose conjugated estrogens and ultra-low-dose estradiol, which are often used in the short term for postmenopausal symptoms, increase BMD, but their antifracture efficacy has not been established.19 Concerns about nonskeletal risks associated with estrogen use (e.g., breast cancer and coronary, cerebrovascular, and thrombotic events)17 have led to recommendations against using estrogen as a first-line therapy for osteoporosis.20 Selective estrogen-receptor modulators (SERMs) activate distinct tissue receptors for estrogen.Raloxifene is a SERM that has been approved by

### Table 1. Guidelines from Professional Organizations for the Treatment of Osteoporosis.

<table>
<thead>
<tr>
<th>Organization</th>
<th>Whom to Treat</th>
<th>Nonpharmacologic Approaches</th>
<th>Pharmacologic Approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Osteoporosis Foundation (United States)7</td>
<td>Women with a previous hip or vertebral fracture, a T score of −2.5 or less at the hip, lumbar spine, or femoral neck, or a T score between −1.0 and −2.5 and a 10-yr probability of hip fracture &gt;3% or of major osteoporotic fracture &gt;20%</td>
<td>Total daily intake (diet plus supplements) of 1200 mg of calcium and 800–1000 IU of vitamin D, regular weight-bearing exercise, fall-prevention strategies, muscle strengthening, and avoidance of smoking and excess alcohol intake</td>
<td>Antiresorptive or anabolic agents, with reassessment after 2–5 yr</td>
</tr>
<tr>
<td>National Osteoporosis Guideline Group (United Kingdom)8</td>
<td>Women with previous fragility fracture; if risk factors are present, use FRAX with or without BMD measurement; treat if FRAX score exceeds age-specific criteria</td>
<td>Maintenance of mobility and correction of nutritional deficiencies, particularly of calcium, vitamin D, and protein†</td>
<td>First-line therapy: generic alendronate; second-line therapies: ibandronate, risedronate, zoledronic acid, denosumab, and raloxifene; teriparatide should be reserved for patients at very high risk for fractures, especially vertebral fractures</td>
</tr>
<tr>
<td>Scientific Advisory Council, Osteoporosis Canada9</td>
<td>Women with previous hip or spine fracture or multiple fractures; assess risk with the 2010 tool of the Canadian Association of Radiologists and Osteoporosis Canada; treat if FRAX score of major osteoporotic fractures is &gt;20%</td>
<td>Resistance exercise, core-stability training, and balance measures; total daily intake of 1200 mg of calcium and 400–1000 IU of vitamin D; aim for serum level of 25-hydroxyvitamin D of &gt;30 ng/ml‡</td>
<td>First-line therapies: alendronate, risedronate, zoledronic acid, and denosumab for prevention of hip, nonvertebral, and vertebral fractures and raloxifene for prevention of vertebral fractures; estrogen for postmenopausal symptoms and prevention of fractures in patients at high risk</td>
</tr>
</tbody>
</table>

*BMD denotes bone mineral density, and FRAX Fracture Risk Assessment Tool.
†Adequate protein intake is essential for maintenance of bone mass.
‡The preferred serum level of 25-hydroxyvitamin D is not firmly established, and other guidelines include levels of 20 ng per milliliter or more.
Table 2. Drugs Approved by the Food and Drug Administration for the Treatment and Prevention of Osteoporosis.*

<table>
<thead>
<tr>
<th>Drug Class and Agent</th>
<th>Method and Frequency of Administration</th>
<th>Type of Fracture Risk Reduction</th>
<th>Side Effects</th>
<th>Approved Use for Osteoporosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bisphosphonates†</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alendronate</td>
<td>Oral: 35–70 mg/wk</td>
<td>Vertebral, nonvertebral, hip</td>
<td>Common: esophagitis, musculoskeletal symptoms; rare: ONJ, atypical femur fractures</td>
<td>Treatment and prevention</td>
</tr>
<tr>
<td>Risedronate</td>
<td>Oral: 35 mg/wk or 150 mg/mo (in a single dose or in two 75-mg doses on consecutive days)</td>
<td>Vertebral, nonvertebral, hip</td>
<td>Common: esophagitis, musculoskeletal symptoms; rare: ONJ, atypical femur fractures</td>
<td>Treatment and prevention</td>
</tr>
<tr>
<td>Ibandronate</td>
<td>Oral: 150 mg/wk; intravenous: 3 mg every 3 mo</td>
<td>Vertebral</td>
<td>Common: first-dose (intravenous) reaction, esophagitis, musculoskeletal symptoms; rare: ONJ, atypical femur fractures</td>
<td>Treatment and prevention</td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td>Intravenous: 5 mg/yr</td>
<td>Vertebral, nonvertebral, hip</td>
<td>Common: acute-phase response (most often after first dose);§ musculoskeletal symptoms; rare: ONJ, atypical femur fractures</td>
<td>Treatment and prevention</td>
</tr>
<tr>
<td><strong>Biologic: denosumab</strong></td>
<td>Subcutaneous: 60 mg every 6 mo</td>
<td>Vertebral, nonvertebral, hip</td>
<td>Common: cellulitis or skin reactions; rare: ONJ, atypical femur fractures</td>
<td>Treatment</td>
</tr>
<tr>
<td><strong>Anabolic: teriparatide</strong></td>
<td>Subcutaneous: 20 μg/day</td>
<td>Vertebral, nonvertebral</td>
<td>Common: nausea, leg cramps; rare: hypercalcemia, osteosarcoma§</td>
<td>Treatment</td>
</tr>
<tr>
<td>Calcitonin¶</td>
<td>Intranasal: 200 IU/day</td>
<td>Vertebral</td>
<td>Nasal congestion</td>
<td>Treatment</td>
</tr>
<tr>
<td>SERM: raloxifene</td>
<td>Oral: 60 mg/day</td>
<td>Vertebral</td>
<td>Venous thromboembolism, hot flashes, leg cramps, nausea</td>
<td>Treatment and prevention</td>
</tr>
<tr>
<td><strong>Estrogens‖</strong></td>
<td></td>
<td></td>
<td>Venous thromboembolism, increased risk of breast cancer and cardiovascular disease</td>
<td>Prevention</td>
</tr>
<tr>
<td>Conjugated equine estrogen</td>
<td>Oral: 0.15–1.25 mg/day</td>
<td>Vertebral, nonvertebral, hip</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17β-estradiol</td>
<td>Oral: 0.025–0.10 mg/day, transdermal: 2 times/wk</td>
<td>No data from randomized trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultra-low-dose 17β-estradiol</td>
<td>Oral: 0.014 mg/day</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ONJ denotes osteonecrosis of the jaw, and SERM selective estrogen-receptor modulator.
†Oral bisphosphonates are also approved in smaller doses for daily use to prevent osteoporosis, but currently those doses are seldom prescribed.
‡Flulike symptoms including fever, arthralgia, or headache may occur after the first administration in up to one third of patients. Symptoms do not last more than 3 days after infusion.§
§There is a black box warning about a risk of osteosarcoma, which has been reported with long-term teriparatide administration in rodents, but only one case in humans has been conclusively related to teriparatide administration.
¶Calcitonin is no longer approved for the treatment of osteoporosis in Europe.
‖Tibolone, which has estrogenic action, is approved for the treatment of postmenopausal osteoporosis in Europe.
the FDA to treat osteoporosis; it inhibits bone resorption, increases spine BMD slightly, and decreases the risk of vertebral fractures by 30% but has no effect on nonvertebral or hip fractures.20 Long-term use of raloxifene decreases breast-cancer risk among high-risk women but increases the risk of thromboembolic events.21,22 Recently, the combination of another SERM, bazedoxifene, with estrogen was approved by the FDA for the treatment of menopausal symptoms and the prevention of osteoporosis but not for the treatment of osteoporosis.

Bisphosphonates
Bisphosphonates inhibit bone remodeling. Several oral and intravenous bisphosphonates have been shown in randomized trials to reduce the risk of fractures.22,23 The bisphosphonates as a class represent the vast majority of prescriptions for osteoporosis treatment, and all are now available in generic form. Although data from randomized trials and clinical experience indicate that they are generally safe, mild hypocalcemia and muscle pain occur infrequently. Two rare but more serious adverse effects have also been observed.24,25 These are atypical femoral fractures (i.e., fractures in the subtrochanteric region that have a transverse orientation and noncomminuted morphologic features, show focal lateral cortical thickening, occur with minimal trauma, and may be bilateral)24 and osteonecrosis of the jaw, which is defined as exposed bone in the maxillofacial region that does not heal within 8 weeks25 (see Areas of Uncertainty, below). Use of bisphosphonates should be limited to persons who have an estimated creatinine clearance greater than 35 ml per minute and normal serum vitamin D levels; symptomatic hypocalcemia can develop in patients with low levels of 25-hydroxyvitamin D who receive concomitant treatment with bisphosphonates.

All oral bisphosphonates have been tested in large, randomized, placebo-controlled trials with fracture end points, among women receiving calcium and vitamin D and daily doses of the bisphosphonates. Oral bisphosphonates are now used in weekly doses (alendronate and risedronate) or monthly doses (ibandronate and risdronate); comparability with daily dosing has been established by assessment of comparative changes in BMD and bone-turnover markers. Minor gastrointestinal irritation may occur with oral bisphosphonates and may be minimized by adherence to dosing instructions. Oral bisphosphonates should not be prescribed for patients with clinically significant esophageal disease (e.g., achalasia).

In the two Fracture Intervention Trials (FIT) of alendronate, which were paired randomized trials (with 3 to 4 years of follow-up) involving postmenopausal women with a BMD T score of −1.6 or less at the femoral neck,26,27 the rate of vertebral fractures was significantly lower (by approximately 50%) among those who received alendronate (at a dose of 5 mg per day for the first 2 years, followed by 10 mg per day) than among those who received placebo. In the first trial (involving women with existing spine fractures), the rate of hip fractures was significantly lower (by 51%) with alendronate, and the rate of nonvertebral fractures was 20% lower with alendronate than with placebo (P=0.06).26 In the second trial (involving women without existing vertebral fractures), the rates of hip and nonvertebral fractures were not significantly lower with alendronate than with placebo overall27 but were significantly lower (nonvertebral fractures by 35% and hip fractures by 56%) in a prespecified subgroup analysis of women with a BMD T score of −2.5 or less at the hip.27,28

Two randomized, controlled trials of risedronate (5 mg per day) in postmenopausal women with existing vertebral fractures, low BMD in the spine, or both showed that over a period of 3 years, the risk of vertebral fractures was lower (by 41 to 49%) with risedronate than with placebo, as was the risk of osteoporotic nonvertebral fractures (by 33 to 40%).29,30 A larger trial with a hip-fracture end point of risedronate (2.5 or 5 mg per day) involving women 70 years of age or older who were at high risk for hip fracture showed a 30% lower rate of such fractures over a period of 3 years with risedronate than with placebo.31 A trial of ibandronate (2.5 mg per day) showed a 62% lower rate of vertebral fractures with ibandronate than with placebo but no reduction in the rate of nonvertebral fractures over a period of 3 years,32 although a post hoc subgroup analysis of women with T scores below −3.0 showed significantly fewer nonvertebral fractures with ibandronate than with placebo.33 Ibandronate is also available in an intravenous formulation (see Table 2 and below).

Adherence to oral bisphosphonates is low, and it is estimated that less than 40% of persons who are prescribed oral medications are still taking them after 1 year.34 Intravenous bisphos-
Denosumab was the first biologic therapy approved to treat osteoporosis. Its action is distinct from that of bisphosphonates: it inhibits bone resorption by binding to the receptor activator of nuclear factor-κB ligand (RANKL), thereby decreasing the differentiation of osteoclasts. Unlike bisphosphonates, it can be used in women with compromised renal function. A large trial involving women with a BMD T score of less than −2.5 but not less than −4.0 at the lumbar spine or total hip showed that treatment with denosumab (60 mg administered twice yearly by subcutaneous injection) resulted in a significantly lower risk of vertebral fractures (by 68%), hip fractures (by 40%), and nonvertebral fractures (by 20%) than the risk with placebo.39 As with bisphosphonates, rare cases of atypical femur fractures and osteonecrosis of the jaw have been observed with denosumab treatment.

Teriparatide

Teriparatide is an anabolic agent that works primarily by increasing bone formation rather than by decreasing resorption. In a 21-month trial involving women with low BMD and previous vertebral fractures, teriparatide (20 μg per day) was associated with a lower risk of vertebral fractures (by 65%) and nonvertebral fractures (by 35%) than the risk with placebo, but not with a lower risk of hip fractures.40 Teriparatide is administered by daily self-injection and is approved for up to 2 years of use. Studies of its use after bisphosphonate treatment have shown that it retains its anabolic properties, although its action is slightly blunted.41 After teriparatide is discontinued, its benefits are quickly lost, so it should be followed by an antiresorptive agent.42 There is a black-box warning about a risk of osteosarcoma associated with teriparatide treatment, on the basis of studies of long-term, high-dose teriparatide in rodents, but to our knowledge only one documented case has been reported in more than 1 million human users.

Areas of Uncertainty

The relative importance of the two rare adverse effects (atypical fractures and osteonecrosis of the jaw) versus the benefits of antiresorptive therapy is uncertain and remains controversial. The concerns of many women regarding these potential adverse effects have increasingly become a substantial barrier to initiation of antosteoporosis therapy and to treatment adherence.43 Atypical fractures have been observed in rare instances in women using bisphosphonates and denosumab. Their pathophysiological mechanisms are unclear. Case–control and cohort studies and analyses of a few randomized trials44-47 have examined the relationship between atypical femoral fractures and osteoporosis treatment (primarily bisphosphonate agents); in all the studies, the incidence of these fractures is low, ranging from approximately 1 in 100,000 to 5 in 10,000 among bisphosphonate users. Atypical fractures constitute only about 4 or 5 of every 1000 femur fractures.44,46 A recent meta-analysis estimated that the relative risk associated with bisphosphonate use was 1.7 (95% confidence interval, 1.2 to 2.4), although there was considerable heterogeneity among studies,45 perhaps reflecting variations in study design and case definition. Several, but not all, studies have suggested an increase in risk with more than 5 years of bisphosphonate use.45 Calculations including results from recent reviews and meta-analyses22,45 suggest a highly favorable benefit-to-risk ratio associated with treatment for up to 5 years in women with osteoporosis, with fewer than 1 event caused per 100 fractures prevented (Table 3).

The incidence of osteonecrosis of the jaw is similarly very low (estimated at <1 case per...
The incidence is much higher among patients with cancer who are taking higher doses of bisphosphonates or denosumab, and co-administration of glucocorticoids or immunosuppressive agents may increase the risk. The American Dental Association in 2011 recommended that osteoporosis therapy does not require alteration before dental procedures. A recent review suggested that before major, invasive dental surgery, consideration should be given to stopping antiresorptive therapy; the review also emphasized the importance of good dental hygiene in reducing risk.

Given concerns about an increased risk of atypical femur fractures with long-term treatment, the possibility of a drug holiday (temporary discontinuation for up to 5 years) has been suggested, although the preferred timing and duration of drug holidays with bisphosphonate therapy are uncertain. Two randomized trials have indicated that with discontinuation of alendronate after 5 years of use or of zoledronic acid after 3 years of use, benefits (as determined primarily by assessment of BMD loss and changes in biochemical markers of bone turnover as compared with those with placebo) are generally retained for up to 5 years. Although the trials were not sufficiently powered to assess fractures, there was a significantly lower incidence of vertebral fractures (clinical vertebral fractures

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. Needed to Treat (3 yr)†</th>
<th>No. of Events Prevented per 1000 Patients Treated (3 yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any nonvertebral, including hip</td>
<td>35</td>
<td>29</td>
</tr>
<tr>
<td>Hip</td>
<td>90</td>
<td>11</td>
</tr>
<tr>
<td>Vertebral fracture (morphometric)</td>
<td>14</td>
<td>71</td>
</tr>
<tr>
<td>Any fracture</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Number of Patients Who Would Need to Be Treated for 3 Years with Bisphosphonates to Prevent One Fracture versus the Hypothetical Number Associated with an Increase of One Atypical Femur Fracture.

† The estimated numbers of patients who would need to be treated with bisphosphonates in order to prevent one fracture were derived from fracture rates, in the active-treatment group as compared with the placebo group, in the Fracture Intervention Trial (for patients with either a vertebral fracture or a BMD T score of less than –2.5 at the hip) for alendronate or in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial for zoledronic acid. The number of events prevented per 1000 patients treated for 3 years refers to fractures that would be prevented by bisphosphonate treatment.

‡ The calculation of the number needed to harm requires the incidence rate among untreated women with osteoporosis as well as the relative risk associated with treatment. The incidence estimate for atypical femur fracture among untreated women with osteoporosis was estimated as 11.5 per 100,000 women followed for 3 years. This was estimated as follows: in the placebo groups from two large randomized trials, the 3-year incidence of hip fractures was approximately 2.5%, which would yield an expected number of 25 hip fractures in 1000 untreated women with osteoporosis followed for 3 years. Then, applying a ratio of 4.6 atypical femur fractures per 1000 hip fractures to the 25 hip fractures yields an expected number of 0.115 atypical fractures over a period of 3 years (11.5 per 100,000 women). The ratio of 4.6 is derived from Schilcher et al. (59 atypical femur fractures among 12,777 femur fractures) and is consistent with another population-based study (22 atypical femur fractures among 5419 femur fractures). We assume four possible relative risks taken from a meta-analysis of bisphosphonates and atypical femur fracture. These include the relative-risk estimate from the full set of studies in the meta-analysis and its lower and upper confidence bounds (relative risk, 1.7; 95% confidence interval, 1.2 to 2.4). In addition, from that same meta-analysis, we include the relative risk (11.8) calculated from the two studies that assessed radiographs of atypical femur fractures according to 2013 American Society for Bone and Mineral Research criteria.

* Adapted from Black et al.
for alendronate and morphometric vertebral fractures for zoledronic acid) among participants who continued bisphosphonate therapy than among those who discontinued therapy. However, neither trial suggested a reduction in non-vertebral fractures among those who continued therapy.

Whereas more data are needed to guide criteria for stopping and restarting therapy, it has been suggested that temporary discontinuations be considered in patients who are at lower risk, as determined on the basis of assessment of hip BMD and vertebral-fracture status at the time of potential discontinuation, and that treatment generally be reinitiated after no longer than 5 years. The value of monitoring therapy after discontinuation with the use of biochemical markers of bone turnover or BMD to aid in clinical decision making about restarting bisphosphonates is controversial. These recommendations regarding drug holidays do not apply to risedronate or ibandronate, because these agents have not been systematically evaluated, or to other osteoporosis therapies, whose benefits are quickly lost after cessation.

**GUIDELINES**

Professional organizations in the United States, United Kingdom, and Canada have provided recommendations for the evaluation and treatment of osteoporosis (see Table 1). The recommendations in this review are largely concordant with these guidelines.

**SUMMARY AND RECOMMENDATIONS**

The woman in the vignette has a low BMD and a fracture history, which are factors that are consistent with osteoporosis. We would recommend increased physical activity, avoidance of smoking and excess alcohol intake, a total calcium intake of 1000 to 1500 mg per day and a total vitamin D intake of 600 to 800 IU per day, and the use of an antiresorptive agent. We would generally recommend a bisphosphonate as first-line therapy if there are no contraindications; we would discuss with the patient the rare potential risks of atypical femur fracture or osteonecrosis of the jaw but also the much greater anticipated benefits in terms of overall reduction in the risk of fractures. Depending on the results of follow-up BMD measurement, we would discuss the possibility of temporarily discontinuing the bisphosphonate after 5 years of treatment.

Dr. Black reports receiving fees for serving on a data and safety monitoring board from Eli Lilly; fees for a presentation and for serving on an advisory board from Amgen, consulting fees from Radius Health, lecture fees and travel support from Merck and Novartis, and grant support from Alexion. Dr. Rosen reports receiving grant support from Alexion. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

---

**REFERENCES**


Copyright © 2016 Massachusetts Medical Society.